News Archive

“The greatest danger in times of turbulence is not the turbulence; it is to act with yesterday’s logic.” Peter Drucker

In a period of massive change, franchises die and are born, previously unimagined models emerge, and incumbents that are too focused on “protecting share” find themselves closing their doors. The healthcare industry represents nearly a fifth of U.S. GDP and it is going through such a period of dramatic change as we speak.  The product companies that dominate the marketplace today find themselves cash rich but growth poor.  At the same time an army of inventors and visionaries in biotechnology, medical devices, diagnostics, health care services, healthcare IT, and consumer health fields are eager to provide a new model for the future.

Ambient Clinical Analytics is a new startup, founded by Mayo Clinic researchers with help from Silicon Valley investors, that aims to bring data assimilation, communication and analytics to the bedside.

Backed by Rock Health and the Social+Capital Partnership, the venture develops decision support tools for intensive care units, operating rooms and emergency departments. Its technologies, which were developed at the Mayo Clinic, enable real-time access to process-of-care information and analytics.

As a direct result of Montgomery County’s ongoing partnership with Chungbuk Province, which includes a Chungbuk Exchange Official who has worked at DED since February 2013, three Korean companies have launched U.S. operations at the County’s Germantown Innovation Center (GIC).

Thursday, May 8, 2014 from 9:00 AM to 5:00 PM (EDT)

Learn from leading investors on syndication:

• Richard Anders, Mass Medical Angels
• Barbara Fox, Avaxia Biologics
• Henry Kay, Launchpad Venture Group
• Reid Leonard, Merck Research Ventures
• Mike McGrail, Cooley LP
• Moderator: Stephen Flaim

Connect with 23 NHLBI companies seeking early-stage investors and partners

• Discover innovative technologies close to commercialization
• Attend a reception to partner and network

Registration is free, but space is limited. Sign up now to save a spot!

More information and agenda to follow.

The Hive is an immersive and informal social environment, dedicated to exploring and showcasing transformative startups and the inspiring entrepreneurs that power the ideas shaping the future of health and medicine.

Our second location will allow us to host The Hive on both coasts – increasing the number of game-changing startups who will join us this coming September 10-12 in either Washington, DC or San Francisco, CA. To help support a growing community of Hive entrepreneurs, we’re re-opening the Hive Application process for two short weeks and applications will be accepted today until April 1.

New Enterprise Associates is up to its neck in initial public offerings these days. But even for NEA, a chipmaker IPO isn’t exactly common.

One of the Chevy Chase-based venture capital firm’s portfolio companies, Milpitas, Calif.-based Aquantia Corp., this week  announced a $16 million Series G financing led by Xilinx Inc., a possible prelude to a public offering for the decade-old semiconductor company, an executive  told The Wall Street Journal.

More than 21 startups presented their technology offerings to Exelon executives and IT employees at “Dancing with Startups,” a two-day event hosted by Exelon and the Economic Alliance of Greater Baltimore at the University of Maryland, Baltimore County, and the Cyber Point Technology & Innovation Center last week.

The event is part of Exelon’s continuing effort to reach out to technology innovators in search of new ideas that have the potential to transform the energy industry. From cybersecurity software to smartphone technology, participating companies pitched their ideas and products during rapid-fire, 20-minute sessions. Exelon employees peppered the groups with questions, seeking to identify new technologies that Exelon might be able to pilot.

People who are prone to bleeding due to poor blood clotting, such as those with hemophilia or on anticoagulants, are often required to take blood tests. These test are usually done in clinics and hospitals, adding to the patient’s burden and expense of extra travel just to make sure that blood is adequately anticoagulated. New technology that is being developed at Qloudlab, a startup based at École polytechnique fédérale de Lausanne (EPFL) in Switzerland, uses capabilities already present in today’s smartphone screens for blood coagulation testing.

Video games have been used in a number of therapeutic applications, such as managing pain in burn victims and helping youngsters deal with depression. A new project in Australia is bringing together video game technology with gesture recognition and some other components to create a virtual reality interactive environment for dementia patients and their caretakers. The project is still in the development stage, and is looking for crowdsourced funds, but the video below shows off the current prototype that will eventually include a 10 m x 10 m projection screen, a touch display, and special lighting.

Pharmaceutical companies have long relied on successfully launching new drugs to drive growth. This pressure is only likely to increase. Patents are expiring and product pipelines are shrinking. Austerity measures in many countries are increasing local and national hurdles for market access. And, at the same time, launches are becoming more numerous, smaller, and more competitive. We estimate that pharmaceutical companies will launch some 400 new products in the next three years, up 146 percent from 2005. Given this changing external landscape, awash with more products of ever greater diversity, it’s never been more important for pharmaceutical companies to crack the new-product launch code.